Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yassmin A. Elbanna"'
Autor:
Shannon E. Elf, Scott A. Oakes, Rebekka K. Schneider, Sandeep Gurbuxani, Steffen Koschmieder, Silvia Catricala, Ilaria Carola Casetti, Daniela Pietra, Elisa Rumi, Jonathan Dowgielewicz, Luke Maxwell, Diane Silva, Benjamin Nicholson, Kathrin Olschok, Milena Kalmer, Julian Baumeister, Julian Lutze, Quinn Smith, Chenyu Liu, Althea Bock-Hughes, Maria Evers, Deborah Rodriguez, Nicole S. Arellano, Harrison S. Greenbaum, Michele Ciboddo, Katarzyna Kurylowicz, Yassmin A. Elbanna, Juan Ibarra
Supplementary Data from Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d504c47564df319c5c1e8f5b6b7e98a
https://doi.org/10.1158/2643-3230.22545003
https://doi.org/10.1158/2643-3230.22545003
Autor:
Shannon E. Elf, Scott A. Oakes, Rebekka K. Schneider, Sandeep Gurbuxani, Steffen Koschmieder, Silvia Catricala, Ilaria Carola Casetti, Daniela Pietra, Elisa Rumi, Jonathan Dowgielewicz, Luke Maxwell, Diane Silva, Benjamin Nicholson, Kathrin Olschok, Milena Kalmer, Julian Baumeister, Julian Lutze, Quinn Smith, Chenyu Liu, Althea Bock-Hughes, Maria Evers, Deborah Rodriguez, Nicole S. Arellano, Harrison S. Greenbaum, Michele Ciboddo, Katarzyna Kurylowicz, Yassmin A. Elbanna, Juan Ibarra
Approximately 20% of patients with myeloproliferative neoplasms (MPN) harbor mutations in the gene calreticulin (CALR), with 80% of those mutations classified as either type I or type II. While type II CALR-mutant proteins retain many of the Ca2+ bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016efe4195fef443d3f9880b5f0730f8
https://doi.org/10.1158/2643-3230.c.6550824
https://doi.org/10.1158/2643-3230.c.6550824
Autor:
Juan Ibarra, Yassmin A. Elbanna, Katarzyna Kurylowicz, Michele Ciboddo, Harrison S. Greenbaum, Nicole S. Arellano, Deborah Rodriguez, Maria Evers, Althea Bock-Hughes, Chenyu Liu, Quinn Smith, Julian Lutze, Julian Baumeister, Milena Kalmer, Kathrin Olschok, Benjamin Nicholson, Diane Silva, Luke Maxwell, Jonathan Dowgielewicz, Elisa Rumi, Daniela Pietra, Ilaria Carola Casetti, Silvia Catricala, Steffen Koschmieder, Sandeep Gurbuxani, Rebekka K. Schneider, Scott A. Oakes, Shannon E. Elf
Publikováno v:
Blood Cancer Discov
Approximately 20% of patients with myeloproliferative neoplasms (MPN) harbor mutations in the gene calreticulin (CALR), with 80% of those mutations classified as either type I or type II. While type II CALR-mutant proteins retain many of the Ca2+ bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16cb5f385956cfd353708e5145af7a62
https://pubmed.ncbi.nlm.nih.gov/35405004
https://pubmed.ncbi.nlm.nih.gov/35405004
